Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 11/20 | 0.61 |
| ▸ | CA2 | P00918 | 4/20 | 0.60 |
| ▸ | CA1 | P00915 | 3/20 | 0.60 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.56 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28353018 | 0.87 | RORC (0.66) | RORCCA2CA1EPHX2NR1H4 | |
| SCHEMBL28909371 | 0.87 | RORC (0.62) | RORCCA2CA1EPHX2NR1H4 | |
| SCHEMBL28266759 | 0.86 | RORC (0.61) | RORCCA2CA1EPHX2NR1H4 | |
| SCHEMBL23632292 | 0.86 | CA1 (0.72) | RORCCA2CA1EPHX2NR1H4 | |
| SCHEMBL28349854 | 0.86 | CA2 (0.64) | RORCCA2CA1EPHX2NR1H4 | |
| SCHEMBL29488705 | 0.85 | RORC (0.71) | RORCCA2CA1ALDH1A1 | |
| SCHEMBL28533261 | 0.83 | RORC (0.59) | RORCCA2CA1EPHX2NR1H4 | |
| SCHEMBL28268476 | 0.83 | EPHX2 (0.65) | RORCCA2CA1EPHX2NR1H4 | |
| SCHEMBL21616581 | 0.83 | RORC (0.62) | RORCCA2CA1EPHX2NR1H4 | |
| SCHEMBL28266766 | 0.81 | RORC (0.57) | RORCCA2CA1EPHX2NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113072476-B | ROR gamma t inhibitor and preparation method and application thereof | 广东东阳光药业股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-112513021-B | ROR gamma antagonist and application thereof in medicines | 广东东阳光药业有限公司 | 2023-06-27 | — | — | CN | disclosed |
| US-20230067159-A1 | ROR-GAMMA-T INHIBITOR, PREPARATION METHOD THEREOF AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2023-03-02 | — | — | US | disclosed |
| EP-4089079-A1 | ROR GAMMA T INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2022-11-16 | — | — | EP | disclosed |
| WO-2021139599-A1 | RORγT INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 东莞市东阳光新药研发有限公司 | 2021-07-15 | — | — | WO | disclosed |
| CN-113072476-A | ROR gamma t inhibitor and preparation method and application thereof | 广东东阳光药业有限公司 | 2021-07-06 | — | — | CN | disclosed |
| CN-112513021-A | ROR gamma antagonist and application thereof in medicine | 广东东阳光药业有限公司 | 2021-03-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230067159-A1 | ROR-GAMMA-T INHIBITOR, PREPARATION METHOD THEREOF AND USE THEREOF | RORC, RORB, RORA | RORC 1/4885CA2 2516/4885CA1 873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.